A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with - 308 TNF gene polymorphism

Scandinavian Journal of Gastroenterology

Volumn 37, Issue 7, 2002, Pages 818-824

  Louis, E ^a   Vermeire, S ^a   Rutgeerts, P ^a   De Vos, M ^a   Van Gossum, A ^a   Pescatore, P ^a   Fiasse, R ^a   Pelckmans, P ^a   Reynaert, H ^a   D'Haens, G ^a   Malaise, M ^a   Belaiche, J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Crohn disease; Genetics; Infliximab; Tumour necrosis factor

Indexed keywords

C REACTIVE PROTEIN; DNA; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DNA EXTRACTION; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; COMPARATIVE STUDY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035988896     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/713786515     Document Type: Article

References (44)

1. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-α for Crohn's disease. Crohn's disease cA2 Study Group
2. Infliximab for the treatment of fistulas in patients with Crohn's disease
3. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
4. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
5. Tumor necrosis factor-α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's enterocolitis
6. Review article: Targeting TNFα as a key cytokine in the inflammatory processes of Crohn's disease - The mechanisms of action of infliximab
7. Tumor necrosis factor: Biology and therapeutic inhibitors
8. Tumor necrosis factor a, interleukin-1β and interleukin-6 expression in inflammatory bowel disease
9. Enhanced secretion of tumor necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease
10. Tumor necrosis factor-α and interleukin 1β in relapse of Crohn's disease
11. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease
12. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production
13. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remisssion in Crohn's disease
14. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis
15. Differing acute phase response in Crohn's disease and ulcerative colitis
16. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study
17. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease
18. DNA sequence polymorphism at the human tumor necrosis factor (TNF) locus. Numerous TNF/lymphotoxin alleles tagged by two closely linked microsatellites in the upstream region of the lymphotoxin gene
19. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles
20. Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor alpha gene promoter
21. Crohn's disease is associated with novel polymorphisms in the 5′-flanking region of the tumor necrosis factor gene
22. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation
23. Secretion of tumor necrosis factor α and lymphotoxin a in relation to polymorphism in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease
24. Tumour necrosis factor (TNF) gene polymorphism influences TNF-α production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans
25. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria
26. Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy
27. Scarring trachoma is associated with polymorphism in the tumor necrosis factor alpha (TNF-α) gene promoter and with elevated TNF-α levels in tear fluid
28. Polymorphism in tumor necrosis factor gene associated with mucocutaneous leishmaniasis
29. Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality
30. Tumour necrosis factor (TNF) gene polymorphism in Crohn's disease (CD); influence on disease behaviour?
31. Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI)
32. Rapide HLA-DQB typing by eight PCR amplifications with sequence-specific primers (PCRSSP)
33. Cytokine gene polymorphisms in inflammatory bowel disease
34. Soluble interleukin-2 receptor in Crohn's disease. Assessment of disease activity and prediction of relapse
35. Inflammatory bowel disease: Etiology and pathogenesis
36. Il-6, TNF-α soluble TNF-α receptor serum level in Crohn's disease
37. Cachectin and tumor necrosis factor as two sides of the same biological coin
38. Relevance of the tumor necrosis factor alpha (TNF alpha)-308 promoter polymorphism in TNF alpha gene regulation
39. Genetic influence on cytokine production and fatal meningococcal disease
40. Evaluation of TNF microsatellites and SNPs in a cohort of chronic active, therapy refractory Crohn's disease patients treated with anti-TNF alpha
41. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo
42. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
43. Chimeric ant-TNF-α monoclonal antibody, cA2, binds recombinant transmembrane TNF-α and activates immune effector functions
44. Mechanisms in failure of infliximab for Crohn's disease